Pharmacodynamics of TNF-α inhibitors in psoriasis

References

• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol.46(1), 1–23 (2002).
   PubMed Web of Science ®Google Scholar
• Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol.113(5), 752–759 (1999).
   PubMed Web of Science ®Google Scholar
• Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J. Autoimmun.14(1), 63–78 (2000).
   PubMed Web of Science ®Google Scholar
• Ovigne JM, Baker BS, Brown DW, Powles AV, Fry L. Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-γ. Exp. Dermatol.10(3), 168–174 (2001).
   PubMedGoogle Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117(2), 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, Khokha R. Cutting edge: tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J. Immunol.176(2), 721–725 (2006).
   PubMed Web of Science ®Google Scholar
• Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science288(5475), 2351–2354 (2000).
   PubMed Web of Science ®Google Scholar
• Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell83(5), 793–802 (1995).
   PubMed Web of Science ®Google Scholar
• Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl Acad. Sci. USA95(2), 570–575 (1998).
   PubMed Web of Science ®Google Scholar
• Hehlgans T, Mannel DN. The TNF–TNF receptor system. Biol. Chem.383(10), 1581–1585 (2002).
   PubMed Web of Science ®Google Scholar
• Seitz C, Muller P, Krieg RC, Mannel DN, Hehlgans T. A novel p75TNF receptor isoform mediating NFκB activation. J. Biol. Chem.276(22), 19390–19395 (2001).
   PubMedGoogle Scholar
• Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology115(1), 1–20 (2005).
   PubMed Web of Science ®Google Scholar
• Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd. Biology of tumor necrosis factor-α – implications for psoriasis. Exp. Dermatol.13(4), 193–222 (2004).
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-α in psoriasis. Am. J. Pathol.138(1), 129–140 (1991).
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. Nuclear factor-κB – a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med.336(15), 1066–1072 (1997).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-a monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol.48(1), 68–75 (2003).
   PubMed Web of Science ®Google Scholar
• Norris DA. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J. Invest. Dermatol.95(Suppl. 6), 111–120 (1990).
   Google Scholar
• Simonetti O, Lucarini G, Campanati A et al. VEGF, survivin and NOS overexpression in psoriatic skin: critical role of nitric oxide synthases. J. Dermatol. Sci.54, 205–218 (2009).
   PubMedGoogle Scholar
• Vergou T, Lima XT, Kimball AB. Targeting the IL12/IL-23 cytokine family in the treatment of psoriatic disease. Exp. Rev. Dermatol.3(4), 453–463 (2008).
   Google Scholar
• Torti DC, Feldman SR. Interleukin-12, interleukin-23 and psoriasis. J. Am. Acad. Dermatol.57, 1059–1068 (2007).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet356(9227), 385–390 (2000).
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther.301(2), 418–426 (2002).
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Trinh H, Nedelman M, Brennan FM, Feldmann M, Ghrayeb J. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine7(8), 759–770 (1995).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol.175(4), 2721–2729 (2005).
   PubMed Web of Science ®Google Scholar
• Zaba LC, Cardinale I, Gilleaudeau P et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med.204(13), 3183–3194 (2007).
   PubMed Web of Science ®Google Scholar
• Lizzul PF, Aphale A, Malaviya R et al. Differential expression of phosphorylated NF-κB/RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. J. Invest. Dermatol.124(6), 1275–1283 (2005).
   PubMed Web of Science ®Google Scholar
• Malaviya R, Sun Y, Tan JK et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J. Am. Acad. Dermatol.55(4), 590–597 (2006).
   PubMedGoogle Scholar
• Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Mol. Immunol.30(16), 1443–1453 (1993).
   PubMed Web of Science ®Google Scholar
• Kohno T, Tam LT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J. Invest. Dermatol. Symp. Proc.12(1), 5–8 (2007).
   PubMedGoogle Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet357(9271), 1842–1847 (2001).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet366(9494), 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Smith CH, Jackson K, Bashir SJ et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br. J. Dermatol.155(1), 160–169 (2006).
   PubMed Web of Science ®Google Scholar
• Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br. J. Dermatol.133(4), 501–511 (1995).
   PubMed Web of Science ®Google Scholar
• Goedkoop AY, Kraan MC, Teunissen MB et al. Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis.63(7), 769–773 (2004).
   PubMed Web of Science ®Google Scholar
• Krüger-Krasagakis S, Galanopoulos VK, Giannikaki L, Stefanidou M, Tosca AD. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br. J. Dermatol.154(3), 460–466 (2006).
   PubMed Web of Science ®Google Scholar
• Bedini C, Nasorri F, Girolomoni G, Pità O, Cavani A. Antitumour necrosis factor-α chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br. J. Dermatol.157(2), 249–258 (2007).
   PubMed Web of Science ®Google Scholar
• Kohno T, Tam L, Ting T, Bass RB, Stevens SR. Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. Arthritis Rheum.52(9), S562–S563 (2005).
   Google Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine7(3), 251–259 (1995).
   PubMed Web of Science ®Google Scholar
• Schmitt J, Wozel G. Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics3, 303–318 (2009).
   PubMedGoogle Scholar
• Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal. Biochem.299(2), 119–129 (2001).
   PubMed Web of Science ®Google Scholar
• Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun.11, 180–210 (2010).
   PubMedGoogle Scholar
• Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J. Invest. Dermatol. Symp. Proc.12(1), 9–15 (2007).
   PubMedGoogle Scholar
• Kohno T, Louie JS, Stevens SR. Differences in Fc receptor and C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action. J. Invest. Dermatol.124(4), A111 (2005).
   PubMedGoogle Scholar
• Kaymakcalan Z, Sakorafas P, Bose S et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin. Immunol.131(2), 308–316 (2009).
   PubMed Web of Science ®Google Scholar
• Antoniou C, Moustou AE, Vergou T, Stratigos A, Kalambokas A, Katsambas AD. Autoimmunity by anti-tumour necrosis factor-α agents: the role of traditional therapies. J. Eur. Acad. Dermatol. Venereol.24(3), 356–357 (2010).
   PubMedGoogle Scholar
• Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine86(4), 242–251 (2007).
   PubMed Web of Science ®Google Scholar
• Elezoglou A, Kafasi N, Kaklamanis PH et al. Infliximab treatment-induced formation of antibodies is common in Behcet’s disease. Clin. Exp. Rheumatol.25(4 Suppl. 45), S65–S69 (2007).
   Google Scholar
• Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J. Am. Acad. Dermatol.61(3), 486–504 (2009).
   PubMed Web of Science ®Google Scholar
• Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis.194(4), 486–492 (2006).
   PubMed Web of Science ®Google Scholar
• Furst DE, Wallis RS, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum.36(3), 159–167 (2006).
   PubMed Web of Science ®Google Scholar